Press Releases

Eisai Inc. and Biogen Inc. are honored to announce today that TIME has selected LEQEMBI® (lecanemab-irmb) as one of the Best Inventions of 2023 in the Medical Care category. LEQEMBI is the first...

Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer's disease New data on subcutaneous formulation shows promising...

Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including...

The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer's disease The Centers for Medicare &...

Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer's...

Treatment with Lecanemab Resulted in a Delay of 2 to 3 Years in the Mean Time to Progression to More Severe Stages of Alzheimer's Disease, Compared with Standard of Care Alone Subgroup Analysis...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from Eisai's Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer's Disease...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ)...

Based on hhc (human health care) concept, our corporate philosophy, Eisai is committed to improve patients health outcomes and quality of life, simplify care delivery, increase health system...

LEQEMBI™ (lecanemab-rimb) has the potential to make a difference for people living with early Alzheimer's disease (AD), their loved ones and healthcare professionals, and was recently approved...

Accelerated Approval is based on Phase 2 data showing a reduction in amyloid-beta plaques in early AD patients treated with LEQEMBI™ Treatment with LEQEMBI should be initiated in patients with...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker findings from the company's Phase 3 confirmatory Clarity AD clinical trial for...

ALL KEY SECONDARY ENDPOINTS ALSO MET, DEMONSTRATING HIGHLY STATISTICALLY SIGNIFICANT RESULTS PROFILE OF AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) INCIDENCE WAS WITHIN EXPECTATIONS EISAI AIMS TO...

C2N Diagnostics and Eisai Inc. today announced the Companies have entered into a memorandum of understanding that will seek to build awareness about how blood-based assays for cognitive...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced that...

Eisai Co. Ltd (Headquarters: Toyoko, CEO: Haruo Naito, "Eisai") announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that lecanemab, an anti-amyloid-β protofibril antibody being developed by Eisai, has no connection regarding...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today a total of seven poster presentations including the latest data on its in-house discovered orexin receptor...